Restless legs syndrome used to feel simple. If the legs were jumping, we reached for a dopamine agonist, the safer alternative to older meds. Over time, we learned that the very medication calming symptoms could make the condition worse. But just as guidelines changed in favor of gabapentin and related medications, new research raised concerns about the medications link to cognitive decline and dementia. So where does that leave patients? In this episode, we will:Define restless legs syndrome and review why dopamine agonists became the standard treatment in the first placeExplain augmentation and rebound in plain language, and why it led to guideline reconsiderationWalk through the AASM’s updated recommendations and why gabapentinoids are now considered first-line therapyExamine the recent study linking gabapentin exposure to increased dementia and mild cognitive impairment riskDiscuss what observational research can and cannot tell us about causationCompare the real-world risks of dopamine agonists versus the emerging safety signals around gabapentinExplore how these recommendations may be interpreted differently by sleep specialists versus primary care providersHighlight the “rock and hard place” many patients feel caught in when every option carries caveatsReview practical strategies: iron optimization, careful dosing, monitoring for augmentation, and individualized careOffer a balanced framework for making thoughtful, evidence-based decisions without panic or oversimplificationProduced by: Maeve WinterMore Twitter: @drchriswinter IG: @drchriwinter Threads: @drchriswinter Bluesky: @drchriswinter The Sleep Solution and The Rested Child Thanks for listening and sleep well!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related